The BRCA1/2 model components include likelihood ratios (LRs) for pathogenicity estimated from clinical data, such as co‐segregation with disease, co‐occurrence with a pathogenic variant in the same gene, reported family history, breast tumor pathology, and more recently, case‐control data (de la Hoya et al., 2016; Easton et al., 2007; Goldgar et al., 2008; Spurdle et al., 2014; Thompson, Easton, & Goldgar, 2003). This evidence concerns the gene BRCA1 and breast neoplasm.